Updates

  1. 137 new fund letters and reports, each with its own page: Kayne Anderson Rudnick (48 market briefings, KayneCast episodes and TV commentaries), Shelton Capital Management (48 shareholder reports and a commentary), Lakehouse Capital (10 Small Companies Fund letters), Smead (5 newsletters), RIT Capital Partners (5 monthly commentaries), Kovitz, Legal & General, Generation, Hosking, Marram, Munro, Oldfield and others.
  2. 200 new fund letters and reports, each with its own page: Spheria (41 monthly reports), Peapack Private (41 weekly recaps and planning newsletters), Fort Washington (23), Polen Capital (15), Aristotle Pacific (14), Riverwater (13), Chou (10), Apollo Asia Fund (8, back to 1998), Personal Asset Trust, Rockwood Strategic, J Capital Research, I/O Fund, Penn Davis McFarland, Pomona and others.
  3. Investor pages have one Investments tab with shares, changes, % owned, class, market cap and Market cap and Status filters, a Funds tab listing each fund the firm runs, and assets under management from Form ADV. The Investors table shows AUM and current investments, and its search finds investors by what they hold.
  4. Filters, search and sort stay as you left them when you come back to a section. Person cards look like book cards. Company pages name their Investors tab Ownership. Kind and Sector filters use four kinds and GICS sectors with industries. Dead links left the Links tabs.
  5. 190 more investors from fiscal.ai's list, with their sites, letters, partners and 13F holdings; 556 more partner descriptions. Experts now lists only people.
  6. Fund letters lists 144 new documents from 23 firms, each with its own page: a summary, key insights and quotes. Among them: 37 BlackRock articles, 21 Value Partners monthly notes, eight Baron Capital letters, six Stone Sentinel letters to partners, seven Value Line portfolio manager Q&As, BNY's 2026 earnings releases and Starboard Value's 2026 conference presentations.
  7. 584 more investors, with their websites, 6,776 letters from their own sites, 1,385 partners with pages and the 13F holdings of 213 firms. New letters arrive daily from 290 more archives.
  8. Media and Companies filter by GICS sector and industry group, taken from the companies an episode or page names. 1,860 more company pages show a logo, the SEC's list included.
  9. The home page counts what the platform holds and lists features such as the document reader, the player and saved marks. Settings sits at the foot of the rail. Book cards are a quarter wider, so rows hold fewer. Companies drops the Named in filter, and the Role list in your account runs A to Z.
  10. Investor pages of 13 firms show their newsroom's latest posts. New 13F filings are read as the SEC publishes them.
  11. Investor pages have an Investments tab: 13,975 holdings for 105 investors, from their 13F filings with the SEC and their own portfolio pages, with status and sector. 7,338 more companies have a page of their own.
  12. A podcast or YouTube episode keeps playing while you move around the site, in a bar with skip, speed and volume. Media tables show each episode's length and description.
  13. Press releases come from each company's own newsroom (167 companies); SEC filings sit on the Filings tab. Tickers name their exchange, and a company's Experts tab includes guests whose episode description names it.
  14. Letter types now include Market commentary, Fact sheet, Interim report, Annual report, Proxy circular and Governance document. The reader opens over the whole window.
  15. Partners of investment firms have 2,836 appearances and 580 pieces of writing on their pages; Derek Sivers's page lists every book he rates, with his rating.
  16. Fund letters lists three Akre Focus shareholder reports: the ETF's annual report for the year to July 2026, its semi-annual report to January 2026 and the fund's semi-annual report to January 2025, each with its own page: a summary, key insights and quotes.
  17. 837 partners of 73 investment firms now have their own pages, with title, description, photograph and social accounts; Andreessen Horowitz partners' pages also list their writing on a16z.com.
  18. Company pages have a Press releases tab: 8,229 releases for 203 companies, from SEC filings and company newsrooms. Companies filter by For-profit or Non-profit. Own media is a table with filters. Media filters by sector and industry. Publication pages link their publisher in the description.
  19. The Unilever page's Letters tab shows what each fund letter says about Unilever, word for word with its page, and whether the letter is bullish, bearish, mixed or neutral. Filter by sentiment, and see 10 letters at a time.
  20. 492 more fund letters and 3,183 more articles show the day they were published, read from each letter's first page or each article's own page.
  21. The PDF reader has a search box: type words to see every match in the document and step through them. About 540 letters that were web pages, among them Oakmark's commentaries, Bill Miller's letters and Howard Marks's memos, now open in the reader.
  22. Person pages: recommendations open with tier 1 books; one button per organisation; transcripts sit on their episodes; the books on 129 reading lists joined the Recommends tabs.
  23. Companies lists every company with a ticker on the SEC's list, with a Source filter. A quote on a company page opens the letter at that page with the words marked. A company's Media tab lists only episodes that name it, and a new Own media tab lists its podcasts, publications and YouTube channel. Show pages link their publisher. A page opened from a table no longer shows that table's filters beside it.
  24. Company, investor and person pages show more of their social accounts: Facebook, TikTok, Bluesky, Medium, GitHub, Discord and podcast shows. Investor pages list every partner the firm's own team page names: 965 people across 73 investors, 98 for Andreessen Horowitz.
  25. About 170 more letters and papers open in the reader: Mohnish Pabrai's letters and transcripts from his site's new folder, and free copies of papers by Asness, Harvey, Altman, Lo and others from their own or their schools' sites.
  26. Every company a fund letter names has a page, with the letters and quotes that name it: 47 new pages, among them Atom Computing, Hugging Face, Rolls-Royce Holdings and Westinghouse Electric. Company pages have a Quotes tab.
  27. A person's Writing tab has a Type column and filter (Article, Essay, Transcript, Speech, Foreword, Interview and the rest), and Publication names only the publication that published each piece.
  28. Fund letters opens on the newest published letter, and a letter or paper found by search opens its own page here instead of the publisher's site.
  29. A letter or paper with a copy on the site opens its PDF over its page, with a button to open it in a new tab. Select text to highlight or underline it; signed-in readers keep their marks in their account. Each quote opens the PDF at its page with its words marked, and a Source link leads to the publisher's original.
  30. Fund letters lists 61 more documents, each with its own page: Fairfax's 2025 and 2026 interim reports, proxy circulars and 2025 annual report (with their French editions), 26 Charlie Munger meeting transcripts, talks and essays, Third Point's 2026 monthly reports and Malibu Life's interim results, and a Seth Klarman interview. Papers adds Richard Thaler's two 2020 editorials on nudges.
  31. Fund letters lists Lux Capital's letters for Q2 and Q3 2026, by Josh Wolfe, each with its own page: a summary, key insights and quotes.
  32. Fund letters lists Brookfield's letter to shareholders for Q3 2026, by Bruce Flatt, with its own page: a summary, key insights and quotes.
  33. Fund letters lists Howard Marks's memo of 11 November 2026, A Layman Thinks About AI, with its own page: a summary, key insights and quotes.
  34. Fund letters lists 118 more letters, each with its own page: 44 weekly commentaries by Jeremy Siegel from 2026, 31 issues of Van Tharp's newsletter from 2018, 23 Pabrai Investment Funds letters from 2021 to Q3 2026, 13 Efficient Frontier essays by William Bernstein, Oakmark's three 3Q 2026 commentaries, two Lindsell Train reports, a John Hussman comment and Third Point's Q3 2026 letter.
  35. 2,027 more books carry a one-line description in the Books table and on their pages; 7,067 of 7,715 have one, every tier 1, 2 and 3 book among them.
  36. Fund letters lists 187 more letters from 19 firms, among them Permanent Equity, Social Capital, Lux Capital, Square Peg, Bestinver, Cobas, Sequoia Fund, Marketfield and EquityCompass; each shows on its investor's page and has a page of its own.
  37. 2,928 more books carry a one-line description in the Books table and on their pages, so every tier 1, 2 and 3 book has one; 5,040 in all.
  38. Every publication on Newsletters has its own page: its writing, its writers, its staff and who recommends it. Investor pages have a Management tab; a company's Experts tab now leaves out its own people, who list under Management. Tabs on a phone move sideways only.
  39. Every fund letter and research paper has its own page: the thesis, the PDF, the companies and books it names, and for 176 letters and 24 papers so far a summary, key insights and quotes with their page.
  40. 99 books that no page listed now sit under their topics in Books, among them Caste, American Prometheus and Pale Blue Dot.
  41. Newsletters lists every newspaper, magazine, investment newsletter, journal and blog the reference holds, 442 in all, with the people who write there. The search box keeps your last 20 searches. You can create an account.
  42. 283 books that fund managers recommend in their letters are on the shelf, each with the letter's own words and page; investor pages have a Recommends tab.
  43. Person, company, investor and show pages link their own accounts on X, Threads, Instagram, LinkedIn, YouTube and Substack: 275 people, 552 companies and organisations, 88 investors and 478 shows.
  44. 716 more book recommendations name their source: the person's own reading list, letter, blog post, speech or interview, or an article that reports it. 232 of them quote the person's own words about the book, on the book card and on the book's page.
  45. Every US-listed company has a page with its SEC filings. Company pages list their experts and their management, past and present. Fund managers sit under Investors. Each show has a page of its episodes, and an episode page names its guests and hosts. Biographies lists groups, then people. Breadcrumbs show where a page sits.
  46. Media lists every podcast episode, video, interview and talk, over 10,000, by person, company, publisher and event; each filter searches its own choices. Books opens on its table, then Browse, then Authors and Recommenders. A filter's count no longer covers its arrow.
  47. A book that no company, country or subject page lists shows its topics under Where it sits in the reference. On a phone, a page's tabs scroll sideways only. Descriptions read the same on every page. See them in the Experts tab lists every expert the page names.
  48. Every podcast episode, video and interview has its own page with a video or audio player and a link to the source. Investor pages show each company's sector and market cap; firms such as Berkshire Hathaway have one page that holds their letters and their company tabs. Letters tabs filter by company and search the theses. Companies filter by Public, Private and Defunct and link each company's website.
  49. Every tab, view and search has its own address, such as /books/table/asset or /letters/companies, so Back works and a link opens the same place. Page addresses no longer end in .html. Fund letters, Investors, Companies and Papers load about a fifth of the data they did.
  50. Fund letters has a Companies tab: every company the letters name, with its market cap, sector, country, and how many letters and investors name it. Investor pages link each investor's website. Lists in table cells end with “… and N more” at every width.
  51. 1,120 more book summaries; descriptions for 373 papers; pages for 137 more companies, each with the fund letters that discuss it; 215 official photographs; search has its own page.
  52. 411 more books have a summary; person pages list 930 more of the books they wrote; 147 people show their official photograph.
  53. Every investor has a page with its letters and the companies they discuss; company pages list the investors whose letters name them.
  54. A Companies section at the top of the rail lists every company the books, experts and fund letters name.
  55. Person pages list letters, writing, profiles and links as sortable tables with filters, and show each person's companies as links; Fund letters show each letter's description in its own column.
  56. Experts show a checked job title and a short description of each person; 30 more people have photographs.
  57. Every company, fund, university and publication the experts work for has a page listing the people there.
  58. Fund letters show each letter's thesis and filter by it; 225 person pages list the essays, columns and newsletter issues the person wrote.
  59. Person pages list every essay and newsletter issue a person wrote, and their own books as a table in List view.
  60. Recommends shows the five largest kinds of book and the rest under More; browse pictures load sooner.
  61. Podcasts and talks link the original episode, filter by Audio and video or Press, and list each publisher once.
  62. Pages are wider, Recommends has List and Grid, and a filter clicked again turns off.
  63. Book cards sit in a ruled grid with Open Library and Goodreads links and each book's one-line note.
  64. Funds is now Investors; each investor's styles are buttons that filter the table.
  65. Podcasts and talks on a person's page filter by year and publisher and show as a list or a grid of pictures.
  66. Quotes show only people's own words: 472 summaries written by list sites are gone.
  67. Country pages open from Browse again, and every link on the shelf lands on a page.
  68. Subject and person pages show their sections as tabs, and each book appears once on a person's page.
  69. Book cards show the quote, who said it and the source; grids show five cards to a row.
  70. On a phone, a menu holds the sections, search, Updates, Feedback and dark mode.
  71. Feedback takes a screenshot of the page with no browser prompt, opens a screenshot full size when you click it, and clears itself once sent.
  72. Book cards are centred, search names the topic each book sits in, and any text cut short shows whole on hover.
  73. Search groups its results by kind: people, companies, geographies, subjects, topics, books, funds, fund letters and papers.
  74. The Books table lists who recommended each book by name, and the browser tab names the section you are in.
  75. Feedback can take a screenshot of the page, or one you paste or choose, and opens in the corner beside Updates.
  76. Each rail button reopens its section where you left it, and Browse, Table and People show on every book and subject page.
  77. Filters grey out choices that hold nothing instead of hiding them, and Books › People filters by authors or recommenders.
  78. Feedback takes a subject line and up to three screenshots.
  79. Biographies are grouped by the person they are about: 41 new pages, from Abraham Lincoln to Lee Kuan Yew.
  80. Sport splits into 23 sports, and Religion into one topic per faith.
  81. Book lists show as cards: the cover, one recommendation quote and every recommender by name.
  82. Seventeen subjects that had two or three pages under different names now have one page each.
  83. Every page lists its Experts as authors and recommenders, with a link to them on the Experts tab.
  84. Economics, Financial history, Financial panics and Accounting are subjects of their own, with one page per financial crisis.
  85. Book, person and subject pages open inside the app, so the tabs stay in view.
  86. 996 more book covers, and photographs or logos for 227 more people and companies.
  87. Books › Browse shows every subject as cards, and the rail holds Fund letters, Papers, Experts, Books and Funds.
  88. Every topic over 150 books splits into narrower topics, each with a page of its own.

Send feedback

What is it?
Screenshots, up to 3 (optional)
or paste one with Ctrl+V

We use your email only to reply to you.

EcoR1 Capital

Asset Manager

AUM: $3.4B · Form ADV, 30 Mar 2026

i
Zymeworks Inc.Nasdaq: ZYMECurrentPharmaceutical PreparationsCOM22,970,38800.0%33.28%$608M+$8M27.01%$1.9BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
ANAPTYSBIO, INCNasdaq: ANABCurrentPharmaceutical PreparationsCOM7,880,09400.0%26.36%$396M-$136M17.58%$1.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
BRISTOL MYERS SQUIBB CONYSE: BMYCurrentPharmaceutical PreparationsCOMNew$218M+$218M9.70%$119BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CG Oncology, Inc.Nasdaq: CGONCurrentBiological Products, (No Diagnostic Substances)COM1,871,892+377,592+25.3%2.10%$133M-$13M5.89%$7.3BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Eton Pharmaceuticals, Inc.Nasdaq: ETONCurrentPharmaceutical PreparationsCOM2,470,920+298,982+13.8%8.57%$127M+$49M5.65%$1.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
First Tracks Biotherapeutics, Inc.Nasdaq: TRAXCurrentPharmaceutical PreparationsORD SHS3,174,51900.0%7.56%$113M+$49M4.99%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Aktis Oncology, Inc.Nasdaq: AKTSCurrentPharmaceutical PreparationsCOM4,824,46900.0%$94M-$62M4.17%$915MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
CRISPR Therapeutics AGNasdaq: CRSPCurrentBiological Products, (No Diagnostic Substances)NAMEN AKT1,389,27600.0%1.43%$77M+$1M3.41%$3.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Alto Neuroscience, Inc.NYSE: ANROCurrentPharmaceutical PreparationsSHSCOM2,232,000+2,232,000New5.56%$57M+$57M2.53%$1.1BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Lakefront Biotherapeutics NVNasdaq: LKFTCurrentPharmaceutical PreparationsSPON ADR1,667,11900.0%$49M-$0.6M2.19%$2.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Erasca, Inc.Nasdaq: ERASCurrentPharmaceutical PreparationsCOM2,950,000+2,620,000+793.9%0.84%$43M+$37M1.92%$5.0BQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Oric Pharmaceuticals, Inc.Nasdaq: ORICCurrentPharmaceutical PreparationsCOM3,028,116-3,700,000-55.0%2.91%$41M-$32M1.81%$800MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Neurogene Inc.Nasdaq: NGNECurrentPharmaceutical PreparationsCOM1,271,34200.0%6.14%$35M-$5M1.57%$475MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Attovia Therapeutics, Inc.Nasdaq: ATTOCurrentBiological Products, (No Diagnostic Substances)COM ADDED2,024,010+2,024,010New4.43%$35M+$35M1.54%$712MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Fulcrum Therapeutics, Inc.Nasdaq: FULCCurrentPharmaceutical PreparationsCOM6,803,785+253,919+3.9%8.91%$25M+$1M1.12%$283MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
ADARx Pharmaceuticals, Inc.Nasdaq: ADRXCurrentPharmaceutical PreparationsCOM ADDED1,150,000+1,150,000New1.03%$23M+$23M1.02%$1.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Stoke Therapeutics, Inc.Nasdaq: STOKCurrentPharmaceutical PreparationsCOM835,000+100,000+13.6%1.28%$22M-$2M0.96%$1.8BQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Zenas BioPharma, Inc.Nasdaq: ZBIOCurrentPharmaceutical PreparationsCOM789,50000.0%1.16%$21M+$1M0.95%$1.7BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Electra Therapeutics, Inc.Nasdaq: ETRACurrentBiological Products, (No Diagnostic Substances)COM ADDED1,700,000+1,700,000New2.70%$19M+$19M0.85%$561MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Atara Biotherapeutics, Inc.Nasdaq: ATRACurrentBiological Products, (No Diagnostic Substances)COM NEW1,552,00000.0%15.23%$13M-$5M0.59%$65MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
CAPRICOR THERAPEUTICS, INC.Nasdaq: CAPRCurrentPharmaceutical PreparationsCOM NEW1,376,580+1,376,580New2.37%$13M+$13M0.58%$438MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Xencor IncNasdaq: XNCRCurrentPharmaceutical PreparationsCOM500,000+500,000New0.67%$12M+$12M0.55%$2.6BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Odyssey Therapeutics, Inc.Nasdaq: ODTXCurrentBiological Products, (No Diagnostic Substances)COMMON STOCK555,55500.0%1.16%$12M+$2M0.55%$882MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Aura Biosciences, Inc.Nasdaq: AURACurrentBiological Products, (No Diagnostic Substances)COM1,666,66700.0%1.60%$10M-$1M0.46%$726MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Nurix Therapeutics, Inc.Nasdaq: NRIXCurrentPharmaceutical PreparationsCOM375,000+105,000+38.9%0.34%$9M+$2M0.39%$1.5BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Braveheart Bio, Inc.Nasdaq: BRVECurrentPharmaceutical PreparationsSHSCOM ADDED416,700+416,700New0.46%$8M+$8M0.37%$1.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Pharvaris N.V.Nasdaq: PHVSCurrentPharmaceutical PreparationsCOM235,00000.0%$7M-$0.7M0.33%$2.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Eikon Therapeutics, Inc.Nasdaq: EIKNCurrentBiological Products, (No Diagnostic Substances)COM855,634+123,028+16.8%1.58%$7M-$3M0.31%$258MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Eloxx Pharmaceuticals, Inc.Nasdaq: ELOXCurrentBiological Products, (No Diagnostic Substances)COM NEW400,00000.0%9.79%$6M+$0.6M0.27%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Aardvark Therapeutics, Inc.Nasdaq: AARDCurrentPharmaceutical PreparationsCOM720,028+323,834+81.7%3.29%$4M+$1M0.17%$22MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
BridgeBio Oncology Therapeutics, Inc.Nasdaq: BBOTCurrentPharmaceutical PreparationsCOM NEW889,607-1,933,519-68.5%1.11%$4M-$18M0.16%$149MQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
TCGX Acquisition Corp.Nasdaq: TCGXCurrentBlank ChecksCL AORD ADDED250,000+250,000New$3M+$3M0.14%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Zura Bio LtdNasdaq: ZURACurrentBiological Products, (No Diagnostic Substances)CLASS A ORD SHS679,715-500,000-42.4%0.71%$3M-$4M0.13%$92MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Helix Acquisition Corp. IIINasdaq: HLXCCurrentBlank ChecksCL A ORD SHS200,00000.0%$2M-$0.0M0.09%Q3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Contineum Therapeutics, Inc.Nasdaq: CTNMCurrentPharmaceutical PreparationsCL A64,303+64,303New$0.9M+$0.9M0.04%$355MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Jazz Pharmaceuticals plcNasdaq: JAZZExitedPharmaceutical PreparationsSHS USD0-1,706,469-100.0%-$323M$15.2BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Centessa Pharmaceuticals PLCExitedSPONSORED ADS0-6,000,000-100.0%-$255MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Uniqure NVExitedSHS0-3,988,971-100.0%-$233MQ4 202517 Feb 2026Q4 2024Q3 202513F, Q3 2025
Crinetics Pharmaceuticals IncExitedCOM0-4,288,120-100.0%-$156MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Prothena Corp PLCExitedSHS0-11,584,280-100.0%-$143MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
PfizerNYSE: PFEExitedPharmaceutical PreparationsCOM-100.0%-$133M$156BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
ARVINAS, INC.Nasdaq: ARVNExitedPharmaceutical PreparationsCOM0-6,726,491-100.0%-$129M$441MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Iteos Therapeutics IncExitedCOM0-10,688,978-100.0%-$107MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Tango Therapeutics, Inc.Nasdaq: TNGXExitedPharmaceutical PreparationsCOM0-10,630,736-100.0%-$89M$3.8BQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Sarepta Therapeutics, Inc.Nasdaq: SRPTExitedPharmaceutical PreparationsCOM0-1,292,386-100.0%-$82M$1.5BQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Apellis Pharmaceuticals IncExitedCOM0-3,447,156-100.0%-$78MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Immunome Inc.Nasdaq: IMNMExitedPharmaceutical PreparationsCOM0-2,855,590-100.0%-$61M$2.0BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Springworks Therapeutics IncExitedCOM0-1,560,000-100.0%-$56MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Viridian Therapeutics, Inc.\DENasdaq: VRDNExitedPharmaceutical PreparationsCOM0-1,958,847-100.0%-$45M$3.6BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Madrigal PharmaceuticalsNasdaq: MDGLExitedPharmaceutical PreparationsCOM0-75,000-100.0%-$34M$9.2BQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Janux Therapeutics, Inc.Nasdaq: JANXExitedPharmaceutical PreparationsCOM0-1,469,818-100.0%-$34M$630MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Edgewise Therapeutics, Inc.Nasdaq: EWTXExitedPharmaceutical PreparationsCOM0-1,250,385-100.0%-$33MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Avidity Biosciences IncExitedCOM0-765,000-100.0%-$33MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Third Harmonic Bio IncExitedCOM0-3,182,444-100.0%-$33MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Akero Therapeutics IncExitedCOM0-440,000-100.0%-$23MQ3 202514 Nov 2025Q1 2025Q2 202513F, Q2 2025
Structure Therapeutics Inc.Nasdaq: GPCRExitedPharmaceutical PreparationsSPONSORED ADS0-334,380-100.0%-$23M$1.2BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Legend Biotech CorpNasdaq: LEGNExitedPharmaceutical PreparationsSPONSORED ADS0-800,000-100.0%-$23M$3.1BQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Celldex Therapeutics, Inc.Nasdaq: CLDXExitedIn Vitro & In Vivo Diagnostic SubstancesCOM NEW0-650,000-100.0%-$22M$2.2BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Neumora Therapeutics, Inc.Nasdaq: NMRAExitedBiological Products, (No Diagnostic Substances)COM0-2,071,450-100.0%-$22M$65MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
MBX Biosciences, Inc.Nasdaq: MBXExitedPharmaceutical PreparationsCOM0-388,500-100.0%-$21M$2.7BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Cargo Therapeutics IncExitedCOM0-1,470,000-100.0%-$21MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Vaxcyte, Inc.Nasdaq: PCVXExitedBiological Products, (No Diagnostic Substances)COM0-450,000-100.0%-$21M$9.2BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
IONIS PHARMACEUTICALS INCNasdaq: IONSExitedPharmaceutical PreparationsCOM0-500,000-100.0%-$20M$4.5BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Verona Pharma PLCExitedSPONSORED ADS0-200,000-100.0%-$19MQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
Tectonic Therapeutic, Inc.Nasdaq: TECXExitedBiological Products, (No Diagnostic Substances)COM0-935,121-100.0%-$19M$411MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
MoonLake ImmunotherapeuticsNasdaq: MLTXExitedPharmaceutical PreparationsCLASS A ORD0-332,522-100.0%-$18M$939MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Aquestive Therapeutics, Inc.Nasdaq: AQSTExitedPharmaceutical PreparationsCOM0-2,625,000-100.0%-$17M$466MQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
Mersana Therapeutics IncExitedCOM0-11,328,000-100.0%-$16MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Voyager Therapeutics, Inc.Nasdaq: VYGRExitedBiological Products, (No Diagnostic Substances)COM0-4,002,847-100.0%-$16M$100MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Alkermes plc.Nasdaq: ALKSExitedPharmaceutical PreparationsSHS0-500,000-100.0%-$15M$7.8BQ4 202517 Feb 2026Q2 2025Q3 202513F, Q3 2025
Metsera IncExitedCOM0-271,529-100.0%-$14MQ4 202517 Feb 2026Q1 2025Q3 202513F, Q3 2025
Kymera Therapeutics, Inc.Nasdaq: KYMRExitedBiological Products, (No Diagnostic Substances)COM0-350,000-100.0%-$14M$10.2BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Dyne Therapeutics, Inc.Nasdaq: DYNExitedPharmaceutical PreparationsCOM0-555,644-100.0%-$13M$3.0BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Relay Therapeutics, Inc.Nasdaq: RLAYExitedBiological Products, (No Diagnostic Substances)COM0-697,948-100.0%-$13M$3.5BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Atea Pharmaceuticals, Inc.Nasdaq: AVIRExitedPharmaceutical PreparationsCOM0-3,341,653-100.0%-$11M$316MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Pacira BioSciences, Inc.Nasdaq: PCRXExitedPharmaceutical PreparationsCOM0-457,471-100.0%-$11M$1.5BQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
Beam Therapeutics Inc.Nasdaq: BEAMExitedBiological Products, (No Diagnostic Substances)COM0-526,685-100.0%-$10M$2.2BQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
MANNKIND CORPNasdaq: MNKDExitedPharmaceutical PreparationsCOM NEW0-1,660,000-100.0%-$9M$1.3BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Nuvation Bio Inc.NYSE: NUVBExitedPharmaceutical Preparations*W EXP 02/10/2020-963,333-100.0%-$9M$1.3BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Prime Medicine, Inc.Nasdaq: PRMEExitedBiological Products, (No Diagnostic Substances)COM0-1,543,326-100.0%-$9M$856MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Ginkgo Bioworks Holdings, Inc.NYSE: DNAExitedBiological Products, (No Diagnostic Substances)CL A NEW0-1,462,328-100.0%-$8M$532MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
LENZ Therapeutics, Inc.Nasdaq: LENZExitedBiological Products, (No Diagnostic Substances)COM0-346,772-100.0%-$8M$105MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
BICYCLE THERAPEUTICS PLCNasdaq: BCYCExitedPharmaceutical PreparationsSPONSORED ADS0-910,000-100.0%-$8M$214MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Kura Oncology, Inc.Nasdaq: KURAExitedPharmaceutical PreparationsCOM0-872,500-100.0%-$8M$675MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Replimune Group, Inc.Nasdaq: REPLExitedBiological Products, (No Diagnostic Substances)COM0-1,000,000-100.0%-$8M$1.8BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Phathom Pharmaceuticals, Inc.Nasdaq: PHATExitedPharmaceutical PreparationsCOM0-625,000-100.0%-$7M$413MQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
Adaptimmune Therapeutics PLCOTC: ADAPYExitedBiological Products, (No Diagnostic Substances)SPONDS ADS0-27,404,070-100.0%-$7MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Verve Therapeutics IncExitedCOM0-1,250,000-100.0%-$6MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Day One Biopharmaceuticals IncExitedCOM0-862,068-100.0%-$6MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
FATE THERAPEUTICS INCNasdaq: FATEExitedBiological Products, (No Diagnostic Substances)COM0-3,049,405-100.0%-$5M$123MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Hillevax IncExitedCOM0-2,420,243-100.0%-$5MQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
Evolus, Inc.Nasdaq: EOLSExitedPharmaceutical PreparationsCOM0-675,000-100.0%-$4M$463MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
BridgeBio Pharma, Inc.Nasdaq: BBIOExitedPharmaceutical PreparationsCOM0-170,172-100.0%-$4M$15.2BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Allovir IncExitedCOM0-408,688-100.0%-$4MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
PepGen Inc.Nasdaq: PEPGExitedPharmaceutical PreparationsCOM0-800,000-100.0%-$4M$370MQ4 202517 Feb 2026Q3 2025Q3 202513F, Q3 2025
Proqr Thrapeutics N VExitedSHS EURO0-1,835,991-100.0%-$3MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Prelude Therapeutics IncNasdaq: PRLDExitedPharmaceutical PreparationsCOM0-947,049-100.0%-$3M$261MQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
iBio, Inc.Nasdaq: IBIOExitedPharmaceutical PreparationsCOM NEW0-1,583,000-100.0%-$3M$56MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Solid Biosciences Inc.Nasdaq: SLDBExitedBiological Products, (No Diagnostic Substances)COM NEW0-744,450-100.0%-$3M$719MQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
Design Therapeutics, Inc.Nasdaq: DSGNExitedPharmaceutical PreparationsCOM0-426,683-100.0%-$3M$597MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Kyverna Therapeutics, Inc.Nasdaq: KYTXExitedBiological Products, (No Diagnostic Substances)COM0-450,000-100.0%-$2M$276MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Generation Bio CoExitedCOM0-2,046,867-100.0%-$2MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Whitehawk Therapeutics, Inc.Nasdaq: WHWKExitedPharmaceutical PreparationsCOM0-1,091,417-100.0%-$2M$184MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Camp4 Therapeutics CorpNasdaq: CAMPExitedPharmaceutical PreparationsCOM0-325,000-100.0%-$2M$251MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
MACROGENICS INCNasdaq: MGNXExitedPharmaceutical PreparationsCOM0-1,602,717-100.0%-$2M$127MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Keros Therapeutics, Inc.Nasdaq: KROSExitedPharmaceutical PreparationsCOM0-187,500-100.0%-$2M$224MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Kalaris Therapeutics, Inc.Nasdaq: KLRSExitedBiological Products, (No Diagnostic Substances)COM0-201,718-100.0%-$2MQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
COMPASS Pathways plcNasdaq: CMPSExitedPharmaceutical PreparationsSPONSORED ADS0-265,137-100.0%-$2M$1.2BQ4 202517 Feb 2026Q3 2025Q3 202513F, Q3 2025
TScan Therapeutics, Inc.Nasdaq: TCRXExitedBiological Products, (No Diagnostic Substances)COM0-662,833-100.0%-$0.9M$10MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Hookipa Pharma IncExitedCOM NEW0-388,861-100.0%-$0.8MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Aligos Therapeutics, Inc.Nasdaq: ALGSExitedBiological Products, (No Diagnostic Substances)COM NEW0-88,569-100.0%-$0.7MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Artiva Biotherapeutics, Inc.Nasdaq: ARTVExitedBiological Products, (No Diagnostic Substances)COM0-41,453-100.0%-$0.4M$189MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Upstream Bio, Inc.Nasdaq: UPBExitedPharmaceutical PreparationsCOM0-60,000-100.0%-$0.4M$110MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Mereo BioPharma Group plcNasdaq: MREOExitedPharmaceutical PreparationsSPON ADS0-1,000,000-100.0%-$0.3M$44MQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
Caremax IncExited*W EXP 06/08/2020-100,000-100.0%-$0.2MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Monte Rosa Therapeutics, Inc.Nasdaq: GLUEExitedBiological Products, (No Diagnostic Substances)COM-100.0%-$0.2M$761MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Allakos IncExitedCOM0-192,346-100.0%-$0.1MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Surrozen, Inc./DENasdaq: SRZNExitedBiological Products, (No Diagnostic Substances)*W EXP 08/01/2030-4,444-100.0%-$0.1MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026